Quantitative analysis of drug delivery to the brain via nasal route

Kozlovskaya, L.N.; Abou-Kaoud, Mohammed; Stepensky, David

doi:10.1016/j.jconrel.2014.06.053

Cited by 281 publications

(205 citation statements)

References 23 publications

Supporting

Mentioning

205

Contrasting

Order By: Relevance

“…A recent empirical analysis uncovered the massive lack of quantitative data in published N2B scientific publications: only 3 % of the studies determine and publish quantitative data like bioavailability or similar [89]. However, the development of a successful N2B technique requires quantitative PK-PD data to engineer a safe and efficient delivering strategy.…”

Section: Intranasal Insulin For Metabolic Diseasesmentioning

confidence: 99%

Nose-to-Brain delivery of insulin for Alzheimer’s disease

Stützle¹,

Flamm²,

Carle

et al. 2015

ADMET DMPK

View full text Add to dashboard Cite

The transport of small molecules, peptides and proteins via the olfactory epithelium and along olfactory and trigeminal nerve pathways from the nasal cavity to the brain is very well known and clinically established for central nervous system (CNS) active drugs like oxytocin, sumatriptan or insulin. Insulin is a clinically well-established biopharmaceutical with a validated function in cognition. Central supply with insulin via intranasal administration improves cognition in animal models CNS delivery -an unmet medical needThe World Health Organization (WHO) estimates that more than a billion people worldwide are suffering from diseases of the central nervous system (CNS; [1,2]). Alzheimer's disease (AD) is the most common neurodegenerative dementia in the industrialized world, with prevalence rates well over 30 % in the over 80-years-old population [1,2]. AD causes enormous costs to the social healthcare systems, as well as personal tragedies for the patients, families and caregivers. Like most neurodegenerative diseases, AD has a poor prognosis and only symptomatic therapy is currently available. Efficient treatment strategies are still limited and an aging society in demographic change presents an enormous challenge to the health systems of industrialized nations. Despite the extensive research and effort to uncover the mechanism of AD pathogenesis, more or less all drug candidates failed to demonstrate significant effects on cognition in clinical trials [3,4].A highly critical point in that context is the low central availability of drugs. The passage of most CNSactive drugs and in particular of biopharmaceuticals is massively hampered by the blood-brain barrier

show abstract

Section: Intranasal Insulin For Metabolic Diseasesmentioning

confidence: 99%

Nose-to-Brain delivery of insulin for Alzheimer’s disease

Stützle¹,

Flamm²,

Carle

et al. 2015

ADMET DMPK

View full text Add to dashboard Cite

show abstract

“…20 Several research suggest that the "nose-to-brain" route is one of the most important developments of pharmaceutical research in brain treatment, including the following: i) the potential to avoid gastrointestinal (GI) and hepatic first-pass metabolism; ii) the possibility of delivering drugs not suitable for oral administration, such as peptides and proteins; and iii) most importantly, the transport of exogenous material directly from the nasal cavity to the brain, thus bypassing the BBB. 21,22 It is known that the unique physiology of the olfactory region within the nasal cavity can provide a direct route of administration to the CNS, through the main innervation of the nasal cavity, that is, the olfactory and trigeminal nerves. 23,24 However, drug delivery via the nose is also limited by a number of factors such as the administration volume, the barrier of the nasal epithelium, the nasal metabolic activity and the presence of a protective mucus layer.…”

Section: Introductionmentioning

confidence: 99%

The nasal delivery of nanoencapsulated statins – an approach for brain delivery

Clementino¹,

Batger²,

Garrastazu³

et al. 2016

IJN

View full text Add to dashboard Cite

“…4,318,319 The intranasal route plays a role in overcoming the BBB and targeting the drugs directly to the brain. 282,[319][320][321][322][323][324][325] However, the oral, dermal, and intravenous routes can be used to administration of nanodevices …”

Section: Remarks and Challengesmentioning

confidence: 99%

Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

Fonseca-Santos¹,

Chorilli²,

Gremião³

2015

IJN

257

160

View full text Add to dashboard Cite

Alzheimer’s disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood–brain barrier. Nanotechnological treatment methods, which involve the design, characterization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via various routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease.

show abstract

Quantitative analysis of drug delivery to the brain via nasal route

Cited by 281 publications

References 23 publications

Nose-to-Brain delivery of insulin for Alzheimer’s disease

Nose-to-Brain delivery of insulin for Alzheimer’s disease

The nasal delivery of nanoencapsulated statins – an approach for brain delivery

Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

Contact Info

Product

Resources

About

Quantitative analysis of drug delivery to the brain via nasal route

Cited by 281 publications

References 23 publications

Nose-to-Brain delivery of insulin for Alzheimer’s disease

Nose-to-Brain delivery of insulin for Alzheimer’s disease

The nasal delivery of nanoencapsulated statins &ndash; an approach for brain delivery

Nanotechnology-based drug delivery systems for the treatment of Alzheimer&rsquo;s disease

Contact Info

Product

Resources

About

The nasal delivery of nanoencapsulated statins – an approach for brain delivery

Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease